Biotie: Formal transfer of global rights for tozadenant to Biotie concluded

BIOTIE THERAPIES CORP.           STOCK EXCHANGE RELEASE             28 August
2014 at 9.00 a.m.

Biotie: Formal transfer of global rights for tozadenant to Biotie concluded

Biotie Therapies Corp. ("Biotie") announces that, following the announcement on
21 March 2014 that Biotie was to regain global rights to tozadenant from UCB
Pharma S.A. (UCB), the companies have now formally agreed the details of the
transfer.

Transfer activities have progressed well to date. This transfer agreement
confirms that UCB will meet all its contractual and scientific commitments
regarding the ongoing development program for tozadenant, which are expected to
be fully completed by the end of 2014. As part of this transfer agreement, UCB
will make a contribution to a portion of the short term development costs
related to the termination, which it will be able to recover from any future
revenues generated from tozadenant by Biotie.

Tozadenant (SYN115), a selective inhibitor of the adenosine 2a (A2a) receptor,
has delivered clinically relevant and statistically highly significant effects
in Parkinson's disease, across multiple pre-specified evaluation parameters, in
a 420 patient Phase 2b study completed in December 2012. It is expected that the
Phase 3 study will be able to start recruiting patients during H1 2015, as
planned.

Timo Veromaa, President and CEO of Biotie commented "We are pleased to have
reached this formal agreement with UCB for the transfer of tozadenant back to
Biotie. We appreciate UCB's significant investment and commitment to the
tozadenant program to-date and remain convinced that tozadenant will provide
significant and clinically meaningful benefits to Parkinson's patients based on
the robust and positive Phase 2b data that has now been published in Lancet
Neurology. We have concluded that the best development strategy to maximize
tozadenant's value to our shareholders is to continue with the Phase 3 study
within our own portfolio. We are currently evaluating various options, which may
include a capital increase, to support the clinical studies and a strong
regulatory filing package for tozadenant."

As part of this agreement, UCB has agreed to certain restrictions on its current
shareholding in Biotie into the next year.

Turku, 28 August 2014

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, virve.nurmi@biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

About tozadenant

Tozadenant is an oral, potent and selective adenosine A2a receptor antagonist
being developed for the treatment of Parkinson's disease. Tozadenant has
displayed clinically relevant and statistically highly significant effects in
Parkinson's disease, across multiple pre-specified evaluation metrics, in a 420
patient Phase 2b study completed in December 2012, and it is currently
transitioning into Phase 3 development.

The preparations for the tozadenant Phase 3 program in Parkinson's disease have
progressed well. These activities include CMC and non-clinical work, and certain
Phase 3 enabling clinical pharmacology studies.

About Biotie

Biotie is a specialized drug development company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development has delivered
Selincro (nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is transitioning into Phase 3 development, and three additional
compounds which are in Phase 2 development for cognitive disorders including
Parkinson's disease dementia, cocaine dependence, and primary sclerosing
cholangitis (PSC), a rare fibrotic disease of the liver.


[HUG#1851445]